Psychiatric symptoms of patients with primary mitochondrial DNA disorders

Behavioral and Brain Functions

Gabriella Inczedy-Farkas²  Viktoria Remenyi²  Aniko Gal²  Zsofia Varga³  Petra Balla¹  Agnes Udvardy-Meszaros⁴  Benjamin Bereznai²  Maria Judit Molnar² 

[1] Department of Psychiatry, Medical School and Health Science Center, University of Debrecen, Debrecen, Hungary

[2] Clinical and Research Center for Molecular Neurology, Department of Neurology, Semmelweis University, 1083 Budapest Tömő Str. 25-29., Budapest, Hungary

[3] Operative Clinical Department Medical Division, Chemical Works of Gedeon Richter Ltd., Budapest, Hungary

[4] Department of Clinical Psychology, Semmelweis University, Budapest, Hungary

关键词: Depression;    Mental disorders;    Mitochondrial mutation;   

Others  :  797550
DOI  :  10.1186/1744-9081-8-9

 received in 2011-09-29, accepted in 2012-02-13,  发布年份 2012

【 摘 要 】

Background

The aim of our study was to assess psychiatric symptoms in patients with genetically proven primary mutation of the mitochondrial DNA.

Methods

19 adults with known mitochondrial mutation (MT) have been assessed with the Stanford Health Assessment Questionnaire 20-item Disability Index (HAQ-DI), the Symptom Check List-90-Revised (SCL-90-R), the Beck Depression Inventory-Short Form (BDI-SF), the Hamilton Depression Rating Scale (HDRS) and the clinical version of the Structured Clinical Interview for the the DSM-IV (SCID-I and SCID-II) As control, 10 patients with hereditary sensorimotor neuropathy (HN), harboring the peripheral myelin protein-22 (PMP22) mutation were examined with the same tools.

Results

The two groups did not differ significantly in gender, age or education. Mean HAQ-DI score was 0.82 in the MT (range: 0-1.625) and 0.71 in the HN group (range: 0-1.625). Level of disability between the two groups did not differ significantly (p = 0.6076). MT patients scored significantly higher on the BDI-SF and HDRS than HN patients (12.85 versus 4.40, p = 0.031, and 15.62 vs 7.30, p = 0.043, respectively). The Global Severity Index (GSI) of SCL-90-R also showed significant difference (1.44 vs 0.46, p = 0.013) as well as the subscales except for somatization. SCID-I interview yielded a variety of mood disorders in both groups. Eight MT patient (42%) had past, 6 (31%) had current, 5 (26%) had both past and current psychiatric diagnosis, yielding a lifetime prevalence of 9/19 (47%) in the MT group. In the HN group, 3 patients had both past and current diagnosis showing a lifetime prevalence of 3/10 (30%) in this group. SCID-II detected personality disorder in 8 MT cases (42%), yielding 3 avoidant, 2 obsessive-compulsive and 3 personality disorder not otherwise specified (NOS) diagnosis. No personality disorder was identified in the HN group.

Conclusions

Clinicians should be aware of the high prevalence of psychiatric symptoms in patients with mitochondrial mutation which has both etiologic and therapeutic relevance.

【 授权许可】

   
2012 Inczedy-Farkas et al; BioMed Central Ltd.

【 参考文献 】

• [1]Goto Y: Clinical and molecular studies of mitochondrial disease. J Inherit Metab Dis 2001, 24:181-188.
• [2]Shoubridge E: Transmission and segregation of the mammalian mitochondrial DNA. In Mitochondrial in Pathogenesis. Edited by Lemasters JJ, Nieminen A-L. New York: Kluwer Academic Publishers; 2002:81-93.
• [3]Clay HB, Sillivan S, Konradi C: Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 2011, 29:311-24.
• [4]Gardner A, Boles RG: Beyond the serotonin hypothesis: Mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:730-43.
• [5]Kuroda Y, Sako W, Goto S, Sawada T, Uchida D, Izumi Y, Takahashi T, Kagawa N, Matsumoto M, Matsumoto M, Takahashi R, Kaji R, Mitsui T: Parkin interacts with Klokin1 for mitochondrial import and maintenance of membrane potential. Hum Mol Genet, in press.
• [6]Calì T, Ottolini D, Brini M: Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease. Biofactors 2011, 37:228-40.
• [7]Parihar MS, Brewer GJ: Mitoenergetic failure in Alzheimer disease. Am J Physiol Cell Physiol 2007, 292:C8-23.
• [8]Smaili SS, Ureshino RP, Rodrigues L, Rocha KK, Carvalho JT, Oseki KT, Bincoletto C, Lopes GS, Hirata H: The role of mitochondrial function in glutamate-dependent metabolism in neuronal cells. Curr Pharm Des 2011, 17:3865-3877.
• [9]Finsterer J: Central nervous system manifestations of mitochondrial disorders. Acta Neurol Scand 2006, 114:217-38.
• [10]Inuwa IM, Peet M, Williams MA: QSAR modeling and transmission electron microscopy stereology of altered mitochondrial ultrastructure of white blood cells in patients diagnosed as schizophrenic and treated with antipsychotic drugs. Biotech Histochem 2005, 80:133-137.
• [11]Cataldo AM, McPhie DL, Lange NT, Punzell S, Elmiligy S, Ye NZ, Froimowitz MP, Hassinger LC, Menesale EB, Sargent LW, Logan DJ, Carpenter AE, Cohen BM: Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol 2010, 177:575-585.
• [12]Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, Rachmanova V: Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001, 55:597-610.
• [13]Andreazza AC, Shao L, Wang JF, Young LT: Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010, 67:360-368.
• [14]Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S: Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004, 61:300-308.
• [15]Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM, Jones EG, Bunney WE, Vawter MP: Mitochondrial involvement in psychiatric disorders. Ann Med 2008, 40:281-295.
• [16]Hovatta I, Juhila J, Donner J: Oxidative stress in anxiety and comorbid disorders. Neurosci Res 2010, 68:261-275.
• [17]Scaglia F: The role of mitochondrial dysfunction in psychiatric disease. Dev Disabil Res Rev 2010, 16:136-143.
• [18]Gardner A, Boles RG: Is a 'mitochondrial psychiatry' in the future? Curr Psychiatr Rev 2005, 1:255-271.
• [19]Fattal O, Link J, Quinn K, Cohen BH, Franco K: Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr 2007, 12:429-438.
• [20]Ponyi A, Borgulya G, Constantin T, Váncsa A, Gergely L, Dankó K: Functional outcome and quality of life in adult patients with idiopathic inflammatorymyositis. Rheumatology 2005, 44:83-8.
• [21]Derogatis LR: SCL-90-R: Administration, Scoring and Procedures Manual. Minneapolis: National Computer Systems; 1994.
• [22]Beck AT, Beck RW: Screening depressed patients in family practice. A rapid technic. Postgrad Med 1972, 52:81-85.
• [23]Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatr 1960, 23:56-62.
• [24]First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington: American Psychiatric Press Inc; 1996.
• [25]First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS: Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II). Washington: American Psychiatric Press Inc; 1997.
• [26]Pál Z, Kiss E, Gál A, Csépány T, Lengyel A, Molnar MJ: Genetically determined neuropathy (CMT 1A) accompanied by immune dysfunction: a case report. Inflamm Res 2009, 58:359-360.
• [27]Aarskog NK, Vedeler CA: Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 2000, 107:494-498.
• [28]Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 1996, 66:2621-2624.
• [29]Parikh S, Saneto R, Falk MJ, Anselm I, Cohen BH, Haas R, Medicine Society TM: A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 2009, 11:414-30.
• [30]Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL: Mitochondrial dysfunction and psychiatric disorders. Neurochem Res 2009, 34:1021-1029.
• [31]Molnar MJ, Perenyi J, Siska E, Nemeth G, Nagy Z: The typical MERRF (A8344G) mutation of the mitochondrial DNA associated with depressive mood disorders. J Neurol 2009, 256:264-265.
• [32]Mancuso M, Ricci G, Choub A, Filosto M, DiMauro S, Davidzon G, Tessa A, Santorelli FM, Murri L, Siciliano G: Autosomal dominant psychiatric disorders and mitochondrial DNA multiple deletions: report of a family. J Affect Disord 2008, 106:173-7.
• [33]Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF: Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatr 2004, 61:450-458.
• [34]Hongpaisan J, Winters CA, Andrews SB: Calcium-dependent mitochondrial superoxide modulates nuclear CREB phosphorylation in hippocampal neurons. Mol Cell Neurosci 2003, 24:1103-1115.
• [35]Nair A, Vaidya VA: Cyclic AMP response element binding protein and brain-derived neurotrophic factor: molecules that modulate our mood? J Biosci 2006, 31:423-434.
• [36]Doering LV, Cross R, Magsarili MC, Howitt LY, Cowan MJ: Utility of observer-rated and self-report instruments for detecting major depression in women after cardiac surgery: a pilot study. Am J Crit Care 2007, 16:260-9.
• [37]Furlanetto LM, Mendlowicz MV, Romildo Bueno J: The validity of the beck depression inventory-short form as a screening and diagnostic instrument for moderate and severe depression in medical inpatients. J Affect Disord 2005, 86:87-91.
• [38]Cervilla JA, Rivera M, Molina E, Torres-Gonzalez F, Bellon JA, Moreno B, de Dios Luna J, Lorente JA, de Diego-Otero Y, King M, Nazareth I, Gutiérrez B, PREDICT Study Core Group: The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT-gene study. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:912-917.
• [39]Munafò MR, Clark TG, Roberts KH, Johnstone EC: Neuroticism mediates the association of the serotonin transporter gene with lifetime major depression. Neuropsychobiology 2006, 53:1-8.
• [40]Willis-Owen SA, Turri MG, Munafò MR, Surtees PG, Wainwright NW, Brixey RD, Flint J: The serotonin transporter length polymorphism, neuroticism, and depression: a comprehensive assessment of association. Biol Psychiatry 2005, 58:451-6.
• [41]Gonda X, Fountoulakis KN, Juhasz G, Rihmer Z, Lazary J, Laszik A, Akiskal HS, Bagdy G: Association of the s allele of the 5-HTTLPR with neuroticism-related traits and temperaments in a psychiatrically healthy population. Eur Arch Psychiatry Clin Neurosci 2009, 259:106-113.
• [42]Suomalainen A, Majander A, Wallin M, Setälä K, Kontula K, Leinonen H, Salmi T, Paetau A, Haltia M, Valanne L, Lonnqvist J, Peltonen L, Somer H: Autosomal dominant progressive external ophthalmoplegia with multiple deletions of mtDNA: clinical, biochemical, and molecular genetic features of the 10q-linked disease. Neurology 1997, 48:1244-53.
• [43]Lacey CJ, Salzberg MR: Obsessive-compulsive disorder with mitochondrial disease. Psychosomatics 2008, 49:540-542.
• [44]Silva MF, Aires CC, Luis PB, Ruiter JP, Ijlst L, Duran M, Wanders RJ, Tavares de Almeida I: Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 2008, 31:205-216.